Anteris Technologies Global Corp. Common Stock (AVR)

• Market cap: $157M
• 1 day: -10.06%
• 5 days: -11.34%
• 1 month: -3.74%
• 3 months: -35.87%
• 6 months: -21.79%
• Year to date: -21.08%
• 1 year: -21.79%
• 5 years: -21.79%
• 10 years: -21.79%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

245% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 11

100% more funds holding

Funds holding: 27 [Q4 2024] → 54 (+27) [Q1 2025]

15.42% more ownership

Funds ownership: 45.27% [Q4 2024] → 60.69% (+15.42%) [Q1 2025]

12% less capital invested

Capital invested by funds: $90.8M [Q4 2024] → $79.5M (-$11.3M) [Q1 2025]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]